Annalisa Jenkins - Feb 24, 2025 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Director
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Stock symbol
SKYE
Transactions as of
Feb 24, 2025
Transactions value $
$0
Form type
4
Date filed
2/26/2025, 05:51 PM
Previous filing
Feb 6, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Stock Option (Right to Buy) Award $0 +35K $0.00 35K Feb 24, 2025 Common Stock 35K $2.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests in equal monthly installments over the one year period beginning February 21, 2025.